SIRION Biotech makes breakthrough in vaccine production
The progress has led to higher production yields, even for vaccine production that has toxic antigens. The scientists expect the new vaccines, which will be on the market soon, to show therapeutic effects within specific fields that have proved to be challenging to address, such as tumor diseases or immune therapies. In the past, creating enough of the vector material for the vaccine has been challenging, especially if the antigens are toxic, with viral or bacterial origin.
At SIRION Biotech, researchers have worked on a development project for two years that used genetic modification to suppress certain antigen production in widespread and inexpensive HEK293 cells during this process. This new cell line solves many of the production problems that are involved in all DNA-based viral vectors that demonstrate toxic proteins throughout the production process.
The new cell line technology can be used to produce many of the DNA-vector based vaccines as well as common vaccine production cell lines.
More details about the cell line will be presented at the upcoming Bio Europe conference in Munich, Germany.